Stock Price Quote

BAFNA PHARMACEUTICALS LTD.

NSE : BAFNAPHBSE : 532989ISIN CODE : INE878I01022Industry : Pharmaceuticals & DrugsHouse : Private
BSE75.00-3.79 (-4.81 %)
PREV CLOSE ( ) 78.79
OPEN PRICE ( ) 78.75
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 1103
TODAY'S LOW / HIGH ( )74.91 82.33
52 WK LOW / HIGH ( )73.35 112.2
NSE74.66-3.93 (-5 %)
PREV CLOSE( ) 78.59
OPEN PRICE ( ) 82.51
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 2164
TODAY'S LOW / HIGH( ) 74.66 82.51
52 WK LOW / HIGH ( )73.25 113
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1995
Management Info
- Chairman - Managing Director
Registered Office

Address Bafna Towers,New No 68, Old No.299,Thambu Chetty Street,
Chennai,
Tamil Nadu-600001

Phone 044- 25267517 / 25270992 / 42677555

Email info@bafnapharma.com

Website www.bafnapharma.com

Registrars Details
Cameo Corporate Services Ltd
Subramanian Buildings No 1 ,Club House Road,,Chennai
Listing : BSE, NSE

NEWS

28Sep Bafna Pharmaceuticals informs about cl
Pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, as..
26Apr Bafna Pharmaceuticals inaugurates QC L
Bafna Pharmaceuticals has inaugurated a new State-of-the-Art Quality Con..
02Feb Bafna Pharmaceuticals informs about bo
Bafna Pharmaceuticals has informed that meeting of board of directors of..
23Sep Bafna Pharmaceuticals informs about re
Bafna Pharmaceuticals has informed that Kamlesh Kumar Babulal (DIN: 0121..
13Jul Bafna Pharmaceuticals informs about ce
Pursuant to Regulation 74(5) of the SEBI (Depository & Participants)..

Financials

in Millions
QTR Dec 24 ANNUAL 24
Net Profit9.4799999999999373.4900000000001
Gross Profit 9.47999999999993 73.4900000000001
Operating Profit 32.5099999999999146.34
Net Sales 331.881524.66

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Ajanta Pharma (BSE)
peergroup  2558.40 (2.61%)
M.Cap ( in Cr)31957.51
Coral Laboratories (BSE)
peergroup  807.60 (8.54%)
M.Cap ( in Cr)288.52
Vimta Labs (BSE)
peergroup  1119.70 (3.91%)
M.Cap ( in Cr)2488.29
Mercury Laboratories (BSE)
peergroup  849.00 (3.78%)
M.Cap ( in Cr)101.88
Aarti Drugs (BSE)
peergroup  410.85 (7.20%)
M.Cap ( in Cr)3749.83

Shareholding Pattern

PROMOTERS 88.3%
NON-INSTITUTION 11.7%
MUTUAL FUNDS/UTI 0%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Bafna Pharmaceuticals Ltd.

Bafna Pharmaceuticals Ltd. was incorporated in the year 1995. Its today's share price is 75. Its current market capitalisation stands at Rs 177.42 Cr. In the latest quarter, company has reported Gross Sales of Rs. 1524.66 Cr and Total Income of Rs.1559.88 Cr. The company's management includes Shanmugam Hemalatha, Akila Chintalapati Raju, A Mohanachandran, Krishna Yeachuri, R Chitra, P K Sundaresan, Upendar Mekala Reddy, Vinayak Dinesh Dendukuri.

It is listed on the BSE with a BSE Code of 532989 , NSE with an NSE Symbol of BAFNAPH and ISIN of INE878I01022. It's Registered office is at Bafna Towers,New No 68, Old No.299,Thambu Chetty StreetChennai-600001, Tamil Nadu. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Abhay Jain & Co, Brahmayya & Co, R Sathyanarayanan & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.